NLS Pharmaceutics AG

NasdaqCM:NLSP Stock Report

Market Cap: US$3.1m

NLS Pharmaceutics Management

Management criteria checks 2/4

NLS Pharmaceutics' CEO is Alex Zwyer, appointed in Aug 2015, has a tenure of 9.42 years. total yearly compensation is $917.00K, comprised of 94.1% salary and 5.9% bonuses, including company stock and options. directly owns 2.46% of the company’s shares, worth $76.31K. The average tenure of the management team and the board of directors is 3.9 years and 2.6 years respectively.

Key information

Alex Zwyer

Chief executive officer

US$917.0k

Total compensation

CEO salary percentage94.1%
CEO tenure9.4yrs
CEO ownership2.5%
Management average tenure3.9yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

NLS Pharmaceutics gets delisting determination letter from Nasdaq

Oct 05

NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate

Sep 27

NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders

Jul 28

Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation

Mar 04
Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation

Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky

Nov 12
Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky

CEO Compensation Analysis

How has Alex Zwyer's remuneration changed compared to NLS Pharmaceutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$917kUS$863k

-US$12m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$15m

Mar 31 2023n/an/a

-US$16m

Dec 31 2022US$1mUS$977k

-US$16m

Sep 30 2022n/an/a

-US$16m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$1mUS$1m

-US$12m

Compensation vs Market: Alex's total compensation ($USD917.00K) is above average for companies of similar size in the US market ($USD645.26K).

Compensation vs Earnings: Alex's compensation has been consistent with company performance over the past year.

CEO

Alex Zwyer (55 yo)

9.4yrs

Tenure

US$917,000

Compensation

Mr. Alexander Zwyer, also known as Alex, M.B.A., Co-Founded NLS Pharmaceutics AG (formerly known as NLS Pharma AG) in 2015 until 2021 and serves as its Chief Executive Officer and Director since August 201...

Leadership Team

NamePositionTenureCompensationOwnership
Alexander Zwyer
Co-Founder9.4yrsUS$917.00k2.46%
$ 76.3k
Eric Konofal
Co-Founder & Chief Scientific Officer3.9yrsUS$179.00k1.7%
$ 52.7k
George Apostol
Chief Medical Officer and Global Head of Research & Development2.3yrsUS$390.00k2.1%
$ 65.1k

3.9yrs

Average Tenure

55yo

Average Age

Experienced Management: NLSP's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alexander Zwyer
Co-Founder9.4yrsUS$917.00k2.46%
$ 76.3k
Ronald Hafner
Independent Chairman of the Board9.4yrsUS$44.00k19.02%
$ 589.2k
Audrey Greenberg
Independent Director1.6yrsUS$152.00kno data
Olivier Samuel
Directorless than a yearno datano data
Gian-Marco de la Cruz
Independent Director3.6yrsUS$30.00k0.41%
$ 12.8k
Florence Aknin
Independent Director1yrno datano data

2.6yrs

Average Tenure

55yo

Average Age

Experienced Board: NLSP's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 02:15
End of Day Share Price 2025/01/21 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NLS Pharmaceutics AG is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
I-Eh JenLaidlaw & Company (UK) Ltd